4.025
0.12%
+0.005
After Hours:
4.0201
-0.0049
-0.12%
Genetron Holdings Ltd ADR stock is currently priced at $4.025, with a 24-hour trading volume of 412.38K.
It has seen a +0.12% increased in the last 24 hours and a +0.12% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.02 pivot point. If it approaches the $4.03 resistance level, significant changes may occur.
Previous Close:
$4.02
Open:
$4.02
24h Volume:
412.38K
Market Cap:
$127.29M
Revenue:
$84.70M
Net Income/Loss:
$-108.35M
P/E Ratio:
-3.4276
EPS:
-1.1743
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.12%
6M Performance:
+19.44%
1Y Performance:
+316.88%
Genetron Holdings Ltd ADR Stock (GTH) Company Profile
Name
Genetron Holdings Ltd ADR
Sector
Industry
Phone
86 10 5090 7500
Address
Building 11, 1-2 Floors Zone 1, No. 8 Life Science Parkway Changping District, Beijing
Genetron Holdings Ltd ADR Stock (GTH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-14-20 | Initiated | BTIG Research | Buy |
Jul-14-20 | Initiated | Canaccord Genuity | Buy |
Genetron Holdings Ltd ADR Stock (GTH) Latest News
Genetron Health Announces Completion of Going Private Transaction
GlobeNewswire Inc.
Genetron Health Announces Shareholders’ Approval of Merger Agreement
GlobeNewswire Inc.
Rare Stock Picks In January 2024 - From 45 Discerning Analysts
Seeking Alpha
Genetron Health to Hold Extraordinary General Meeting of Shareholders
GlobeNewswire Inc.
Spirit-JetBlue And 14 Other Opportunities In The Merger Arbitrage Space
Seeking Alpha
Genetron Holdings Ltd ADR Stock (GTH) Financials Data
Genetron Holdings Ltd ADR (GTH) Revenue 2024
GTH reported a revenue (TTM) of $84.70 million for the quarter ending June 30, 2022, a +17.14% rise year-over-year.
Genetron Holdings Ltd ADR (GTH) Net Income 2024
GTH net income (TTM) was -$108.35 million for the quarter ending June 30, 2022, a -118.61% decrease year-over-year.
Genetron Holdings Ltd ADR (GTH) Earnings per Share 2024
GTH earnings per share (TTM) was -$3.5229 for the quarter ending June 30, 2022, a -114.48% decline year-over-year.
About Genetron Holdings Ltd ADR
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Cap:
|
Volume (24h):